BMO
BIS icon

Beck Mack & Oliver’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Beck Mack & Oliver’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,250
Closed -$602K – 372
2014
Q3 		$602K Buy
+1,250
New +$665K 0.01% 220

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
KC
Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Beck Mack & Oliver's BIS Position: Q4 2014 in Review

Beck Mack & Oliver sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2014, closing a stake of 1,250 shares — an estimated $602K sold.

Beck Mack & Oliver first reported a position in BIS in Q3 2014 and held it in 1 quarter. The position peaked at $602K in Q3 2014. 9 funds tracked by Wall St. Rank hold BIS as of Q4 2014.

  • Beck Mack & Oliver reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Beck Mack & Oliver sold 1,250 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2014, an estimated $602K.
  • Beck Mack & Oliver first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2014 and held it in 1 quarter.
  • Beck Mack & Oliver's ProShares UltraShort NASDAQ Biotechnology position peaked at $602K in Q3 2014.
  • 9 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2014.

Based on Beck Mack & Oliver's 13F filing for Q4 2014, filed 26 Jan 2015.